Intra-tumour heterogeneity – going beyond genetics

FEBS Journal

Volumn , Issue , 2016, Pages 2245-2258

  Caiado, Francisco ^a   Silva Santos, Bruno ^a   Norell, Håkan ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

cancer mutation; cancer stem cells; clonal evolution; leukaemia initiating cells; lineage tracing; next generation sequencing; non genetic variability; population dynamics; single cell transcriptomics; sub clone

Indexed keywords

RNA;

ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL TRACKING; CLONAL EVOLUTION; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMAN; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84976489749     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13705     Document Type: Article

References (90)

1. Brown TM & Fee E (2006) Rudolf Carl Virchow: medical scientist, social reformer, role model. Am J Public Health 96, 2104–2105.
2. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R & Heppner GH (1978) Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38, 3174–3181.
3. Pertschuk LP, Tobin EH, Brigati DJ, Kim DS, Bloom ND, Gaetjens E, Berman PJ, Carter AC & Degenshein GA (1978) Immunofluorescent detection of estrogen receptors in breast cancer. Comparison with dextran-coated charcoal and sucrose gradient assays. Cancer 41, 907–911.
4. Poste G, Doll J, Hart IR & Fidler IJ (1980) In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 40, 1636–1644.
5. Raz A, McLellan WL, Hart IR, Bucana CD, Hoyer LC, Sela BA, Dragsten P & Fidler IJ (1980) Cell surface properties of B16 melanoma variants with differing metastatic potential. Cancer Res 40, 1645–1651.
6. Mitelman F, Mark J, Levan G & Levan A (1972) Tumor etiology and chromosome pattern. Science 176, 1340–1341.
7. Shapiro JR, Yung WK & Shapiro WR (1981) Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 41, 2349–2359.
8. Danielson KG, Anderson LW & Hosick HL (1980) Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res 40, 1812–1819.
9. Gray JM & Pierce GB (1964) Relationship between growth rate and differentiation of melanoma in vivo. J Natl Cancer Inst 32, 1201–1210.
10. Barranco SC, Ho DH, Drewinko B, Romsdahl MM & Humphrey RM (1972) Differential sensitivites of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res 32, 2733–2736.
11. Makino S & Kano K (1953) Cytological studies of tumors. IX. Characteristic chromosome individuality in tumor strain-cells in ascites tumors of rats. J Natl Cancer Inst 13, 1213–1235.
12. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194, 23–28.
13. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M et al. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66–72.
14. Polyak K (2014) Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat Med 20, 344–346.
15. Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR et al. (2014) Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46, 225–233.
16. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366, 883–892.
17. Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH & Gabbert HE (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16, 790–799.
18. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J et al. (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809–813.
19. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117.
20. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin M-L et al. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109–1113.
21. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJH, Witt H, Croul S, Bouffet E, Fults DW, Eberhart CG et al. (2012) Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482, 529–533.
22. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472, 90–94.
23. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, Riggs M, Eberling Y, Troge J, Grubor V et al. (2010) Inferring tumor progression from genomic heterogeneity. Genome Res 20, 68–80.
24. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques R-A, Rabinovitch PS et al. (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38, 468–473.
25. Bochtler T, Stölzel F, Heilig CE, Kunz C, Mohr B, Jauch A, Janssen JWG, Kramer M, Benner A, Bornhäuser M et al. (2013) Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol 31, 3898–3905.
26. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S et al. (2015) Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525–530.
27. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L et al. (2013) Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714–726.
28. Kleppe M & Levine RL (2014) Tumor heterogeneity confounds and illuminates: assessing the implications. Nat Med 20, 342–344.
29. Andor N, Graham TA, Jansen M, Xia LC, Aktipis CA, Petritsch C, Ji HP & Maley CC (2015) Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med 22, 105–113.
30. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD et al. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506–510.
31. Greaves M & Maley CC (2012) Clonal evolution in cancer. Nature 481, 306–313.
32. Paguirigan AL, Smith J, Meshinchi S, Carroll M, Maley C & Radich JP (2015) Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med 7, 281re2.
33. Hughes AEO, Magrini V, Demeter R, Miller CA, Fulton R, Fulton LL, Eades WC, Elliott K, Heath S, Westervelt P et al. (2014) Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 10, e1004462.
34. Desai MM, Walczak AM & Fisher DS (2013) Genetic diversity and the structure of genealogies in rapidly adapting populations. Genetics 193, 565–585.
35. Desai MM & Fisher DS (2007) Beneficial mutation selection balance and the effect of linkage on positive selection. Genetics 176, 1759–1798.
36. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F & Polyak K (2014) Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514, 54–58.
37. Kvitek DJ & Sherlock G (2013) Whole genome, whole population sequencing reveals that loss of signaling networks is the major adaptive strategy in a constant environment. PLoS Genet 9, e1003972.
38. Herron MD & Doebeli M (2013) Parallel evolutionary dynamics of adaptive diversification in Escherichia coli. PLoS Biol 11, e1001490.
39. Lang GI, Rice DP, Hickman MJ, Sodergren E, Weinstock GM, Botstein D & Desai MM (2013) Pervasive genetic hitchhiking and clonal interference in forty evolving yeast populations. Nature 500, 571–574.
40. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB & Loeb LA (2012) Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A 109, 14508–14513.
41. Ding L, Raphael BJ, Chen F & Wendl MC (2013) Advances for studying clonal evolution in cancer. Cancer Lett 340, 212–219.
42. Van Loo P & Voet T (2014) Single cell analysis of cancer genomes. Curr Opin Genet Dev 24, 82–91.
43. Grün D & van Oudenaarden A (2015) Design and analysis of single-cell sequencing experiments. Cell 163, 799–810.
44. Jones S, Chen W-D, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE et al. (2008) Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 105, 4283–4288.
45. Loreau M, Naeem S, Inchausti P, Bengtsson J, Grime JP, Hector A, Hooper DU, Huston MA, Raffaelli D, Schmid B et al. (2001) Biodiversity and ecosystem functioning: current knowledge and future challenges. Science 294, 804–808.
46. Flynn DFB, Mirotchnick N, Jain M, Palmer MI & Naeem S (2011) Functional and phylogenetic diversity as predictors of biodiversity–ecosystem-function relationships. Ecology 92, 1573–1581.
47. True HL & Lindquist SL (2000) A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 407, 477–483.
48. Lewis K (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5, 48–56.
49. Kreso A, O'Brien CA, van Galen P, Gan OI, Notta F, Brown AMK, Ng K, Ma J, Wienholds E, Dunant C et al. (2013) Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543–548.
50. Almendro V, Marusyk A & Polyak K (2013) Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 8, 277–302.
51. Baylin SB & Jones PA (2011) A decade of exploring the cancer epigenome – biological and translational implications. Nat Rev Cancer 11, 726–734.
52. Iorio MV & Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4, 143–159.
53. Easwaran H, Tsai H-C & Baylin SB (2014) Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54, 716–727.
54. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA & Kinzler KW (2013) Cancer genome landscapes. Science 339, 1546–1558.
55. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R & Lichter P (2013) Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet 14, 765–780.
56. Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S et al. (2014) Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 26, 813–825.
57. Oakes CC, Claus R, Gu L, Assenov Y, Hüllein J, Zucknick M, Bieg M, Brocks D, Bogatyrova O, Schmidt CR et al. (2014) Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov 4, 348–361.
58. Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, Oakes C, Zucknick M, Lipka DB, Weischenfeldt J et al. (2014) Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep 8, 798–806.
59. Mazor T, Pankov A, Johnson BE, Hong C, Hamilton EG, Bell RJA, Smirnov IV, Reis GF, Phillips JJ, Barnes MJ et al. (2015) DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28, 307–317.
60. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80.
61. Bonnet D & Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730–737.
62. Kreso A & Dick JE (2014) Evolution of the cancer stem cell model. Cell Stem Cell 14, 275–291.
63. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C & Lander ES (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633–644.
64. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J et al. (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17, 1086–1093.
65. Beerman I & Rossi DJ (2015) Epigenetic control of stem cell potential during homeostasis, aging, and disease. Cell Stem Cell 16, 613–625.
66. Greaves M (2013) Cancer stem cells as “units of selection”. Evol Appl 6, 102–108.
67. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J et al. (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361.
68. Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L, Ballerini P, Baruchel A, Pflumio F & Soulier J (2011) Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 208, 653–661.
69. Notta F, Mullighan CG, Wang JCY, Poeppl A, Doulatov S, Phillips LA, Ma J, Minden MD, Downing JR & Dick JE (2011) Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469, 362–367.
70. Munsky B, Neuert G & van Oudenaarden A (2012) Using gene expression noise to understand gene regulation. Science 336, 183–187.
71. Raj A, Rifkin SA, Andersen E & van Oudenaarden A (2010) Variability in gene expression underlies incomplete penetrance. Nature 463, 913–918.
72. Cohen AA, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A, Milo R, Cohen-Saidon C, Liron Y, Kam Z et al. (2008) Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511–1516.
73. Hanahan D & Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322.
74. Chen Q, Zhang XH-F & Massagué J (2011) Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20, 538–549.
75. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E & Joyce JA (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 25, 2465–2479.
76. Livet J, Weissman TA, Kang H, Draft RW, Lu J, Bennis RA, Sanes JR & Lichtman JW (2007) Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 450, 56–62.
77. Blundell JR & Levy SF (2014) Beyond genome sequencing: lineage tracking with barcodes to study the dynamics of evolution, infection, and cancer. Genomics 104, 417–430.
78. Naik SH, Schumacher TN & Perié L (2014) Cellular barcoding: a technical appraisal. Exp Hematol 42, 598–608.
79. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K et al. (2011) Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9, 357–365.
80. Stoyanova T, Cooper AR, Drake JM, Liu X, Armstrong AJ, Pienta KJ, Zhang H, Kohn DB, Huang J, Witte ON et al. (2013) Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A 110, 20111–20116.
81. Nguyen LV, Cox CL, Eirew P, Knapp DJHF, Pellacani D, Kannan N, Carles A, Moksa M, Balani S, Shah S et al. (2014) DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts. Nat Commun 5, 5871.
82. Porter SN, Baker LC, Mittelman D & Porteus MH (2014) Lentiviral and targeted cellular barcoding reveals ongoing clonal dynamics of cell lines in vitro and in vivo. Genome Biol 15, R75.
83. Bhang HC, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P et al. (2015) Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med 21, 440–448.
84. Chibon F (2013) Cancer gene expression signatures – the rise and fall? Eur J Cancer 49, 2000–2009.
85. devan Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999–2009.
86. Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Della Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NCP, Vyas P et al. (2015) Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nat Commun 6, 5901.
87. Wu AR, Neff NF, Kalisky T, Dalerba P, Treutlein B, Rothenberg ME, Mburu FM, Mantalas GL, Sim S, Clarke MF et al. (2014) Quantitative assessment of single-cell RNA-sequencing methods. Nat Methods 11, 41–46.
88. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL et al. (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396–1401.
89. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J et al. (2015) RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science (80-.) 349, 1351–1356.
90. Junker JP & van Oudenaarden A (2015) Single-cell transcriptomics enters the age of mass production. Mol Cell 58, 563–564.